ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Gilead’s Kite adds cell therapy manufacturing capacity

by Lisa M. Jarvis
May 21, 2018 | APPEARED IN VOLUME 96, ISSUE 21

 

Gilead Sciences-owned Kite Pharma is investing in cell therapy manufacturing in Europe. Kite has leased a site in Hoofddorp, the Netherlands, that will allow it to make highly personalized treatments, including the CAR T-cell therapy axicabtagene ciloleucel, which is sold in the U.S. as Yescarta and is under European regulatory review. Kite recently added research and manufacturing capacity in the U.S. when it acquired a building in Santa Monica, Calif., from Astellas Pharma and leased a facility in Gaithersburg, Md.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment